Author Archives: admin


Stem Cell Clinic > Articles by: admin

Mum whose husband died of coronavirus shares heartbreaking video of one-year-old son saying Dada as his fir – The Irish Sun

By Stem Cell Doctors

A MUM whose husband died of coronavirus complications has shared a heartbreaking video of their one-year-old son saying "Dada" as his first words.

Broadway star Nick Cordero tragically passed away last month - leaving behind his devastated wife Amanda Kloots-Larsen and their baby son Elvis.

5

Posting on her Instagram page, Amanda shared an emotional clip of Elvis pointing at a picture of his father and saying "Dada right there".

In the video, the tot reaches for the picture light which is covered in images of his dad and gives it a kiss.

Alongside the video, Amanda wrote: "[Elvis] hasnt seen Nick since March 30th.

"The fact that he still knows who his Dada is, point to him and give him a kiss to me is amazing."

5

5

Earlier this week, Amanda revealed on social media that her and Elvis are moving into the house in LA she had purchased with her late husband.

Nick tragically caught coronavirus when he was packing up his home in New York - and was originally misdiagnosed with pneumonia when he returned to Los Angeles.

Doctors were not onlyforced to amputate Nick's right leg as a result of blood clots, but the Broadway star also had to undergo stem cell treatment to strengthen his lungs.

But on July 5, 2020Nick sadly passed away after 91 days in hospital.

5

5

Explaining how she was putting on a "brave face" for her son, Amanda wrote: "Im not expecting this to be easy, in fact I think it will be very hard, but Im going into it knowing I need to be strong.

"I have to find my new normal, at least whatever that is for Elvis and I right now. I know Nick will be with us.

"He wanted to live in this house more than anything so Ill put lots of family photos up and make sure his presence is with us."

Amanda's video of Elvis' first words has been viewed by over 296,000 users on Instagram - and it left fans in tears.

"Beautiful moment," one replied. "Thank you for sharing with us."

Another added: "My heart is happy and sad at the same time."

"How precious," a third wrote. "He clearly remembers his Dadda."

For more real life stories, this mum's pregnancy made her so sick she felt suicidal and asked for an abortion.

And this mum thought her daughter would be safe at nursery but an accident almost blinded her & she needed five-hour eye surgery.

Plus this woman grew up thinking her mum tried to kill her in a fire which left her with horrific scars but she wont lie to my son about the past.

More:
Mum whose husband died of coronavirus shares heartbreaking video of one-year-old son saying Dada as his fir - The Irish Sun

Clinical Laboratory Services Market – Detailed Analysis of Current and Future Industry Figures till 2027 | Global Players Mayo Foundation for Medical…

By Gene Therapy Clinics

Clinical Laboratory Services Market

Data Bridge Market Research (DBMR) has published a latest market research report on Global Clinical Laboratory Services Market . The global report is prepared in collaboration with the leading industry experts & dedicated research analyst team to provide an enterprise with in-depth market insights & help them to take crucial business decisions. This report covers current market trends, opportunities, challenges & detailed competitive analysis of the industry players in the market.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-clinical-laboratory-services-market&rp

This Clinical Laboratory Services market report practices the latest tools and techniques for researching, analysing and assembling data and information. The market study conducted in this large scale market report spans diverse markets in accord with the requirement of Healthcare industry and scoop out the most promising solutions and in-depth information about the market trends.

Market Analysis and Insights:Global Clinical Laboratory Services Market

Clinical laboratory services market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.2% in the forecast period of 2020 to 2027 and expected to reach USD 217,941.33 million by 2027 from USD 134,692.52 million in 2019. Rising demand for early and accurate disease diagnosis is the factors for the market growth.

The major players covered in theClinical Laboratory Services MarketareMayo Foundation for Medical Education and Research (MFMER), Laboratory Corporation of America Holding, Quest Diagnostics Incorporated, Spectra Laboratories (A Subsidiary of Fresenius Medical Care AG & Co. KGaA), DaVita Inc., Eurofins Scientific, UNILABS, SYNLAB International GmbH, MIRACA HOLDINGS Inc., Sonic Healthcare, ACM Global Laboratories, amedes Group, LifeLabs, Alere (A Subsidiary of Abbott), Charles River, Siemens Healthineers AG, BioReference Laboratories, Inc., NeoGenomics Laboratories, Inc., KingMed Diagnostics, Genomic Health, among other players domestic and global.Clinical laboratory services market share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-clinical-laboratory-services-market&rp

Clinical laboratory services is playing significant role to enable doctors to make appropriate clinical and diagnostic decisions across various levels of health care services. Increasing demand for diagnostic tests is augmenting the market growth as they are used for clinical diagnoses tests.

Clinical laboratory services demand has been increased with rising infectious diseases worldwide as compared to the past few years which will accelerate the market growth. Clinical diagnostic advancement methods for diagnoses of diseases in the clinical laboratory. For instance, Technological advancement in the clinical diagnostic methods have made diagnostic tests easier to use and more accurate as well as also led to more precise as well as more timely reports. Development in database management tools and wide acceptance of point-of-care (POC) testing solutions will also drive the market. Lack of skilled and certified professionals will hamper the Clinical laboratory services market as which further creates new opportunities for clinical laboratory services with growing adoption of digital pathology platforms. Such policies support Clinical Laboratory Services market growth in the forecast period to 2027.

This clinical laboratory services market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Clinical Laboratory Services Market Scope and Market Size

Global clinical laboratory services market is segmented of the basis of specialty, provider and application. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on specialty, the market is segmented into clinical chemistry testing, microbiology testing, hematology testing, immunology testing, cytology testing, genetic testing and drugs of abuse testing. The clinical chemistry testing segment is dominating the market due to the growing cases of chronic diseases such as liver diseases, cardiovascular diseases and blood disorders which are increasing the demand to use clinical chemistry services. Additionally, the increasing demand of point of care testing solutions which is used for the fast diagnosis of the disease is expected to help the market to growth significantly.

Rising demand of clinical laboratory services across the world is one of the prominent factors for increasing demand of clinical chemistry testing. For instance, yearly in the U.K., the usually citizen has 14 tests completed by a laboratory specialist. However in the U.S., laboratory testing is the only highest-volume medical activity and approximately 13,000 million tests are performed per year. Hence, this factor has led the patients to shift towards clinical chemistry testing because it offers a wide range of tests which are performed in the clinical laboratory testing. In the current scenario the technological advancements boost the patients reach to laboratory testing, which is becoming gradually more precise and affordable. For instance, point-of-care testing (POCT) is regularly applied in hospitals and other healthcare practices, so the patients not need to travel to the clinical laboratories for testing. The increasing use of point-of-care testing has reduced demand tests which are conventionally executed at industry laboratories.

Rising demand of early and accurate disease diagnosis across the globe is one of the prominent factors for an upsurge demand of clinical laboratory services. For instance, in 2018, World Health Organization projected that projected that an estimated 1.8 million new cases and almost 861,000 deaths occur due to colorectal cancer (CRC). This factor has increased the number of clinical laboratories around the globe as Delays in accessing cancer care are very common in the late-stage presentation, especially in lower vulnerable populations and resource settings.

Based on provider, the market is segmented into independent & reference laboratories, hospital-based laboratories, nursing and physician office-based laboratories. The hospital-based laboratories segment is dominating the market due to increasing cases of injuries in the hospitals which leads to the high patient volumes and high test demand. Additionally, the rising inclination of retail clinics for disease monitoring is expected to positively impact in the demand of hospital-based laboratories. Competences of hospitals for acquiring novel technologies and hiring of trained professionals in the disease testing units has created an opportunity for the highest revenue generation. Additionally, the clinical labs are more crucial part of any hospital.

Based on application, the market is segmented into drug discovery related services, drug development related services, bioanalytical & lab chemistry services, toxicology testing services, cell & gene therapy related services, and preclinical & clinical trial related services and other clinical laboratory services. Bioanalytical & lab chemistry services segment is dominating the market because bioanalysis is an important factor in drug discovery and development. It is established that bioanalysis is a vital part of the pharmacokinetic/pharmacodynamic categorization of a novel chemical entity from its discovery and in different phases of drug development including all preclinical and clinical stages. Additionally, lab chemistry services provide support in the chemical analysis including elemental analysis, failure analysis and project analysis.

Clinical Laboratory Services Market Country Level Analysis

The global clinical laboratory services market is analysed and market size information is provided by country by specialty, provider and application as referenced above.

The countries covered in the clinical laboratory services market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, South Africa, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil and Rest of South America as part of South America.

Country Level Analysis, By Provider

North America dominates the clinical laboratory services market as the U.S. is leader in clinical laboratory services. In North America due to better advancement in products and services, this region is dominating the clinical laboratory services. North America accounts higher healthcare expenditure, especially in U.S. Asia-Pacific is growing with the highest CAGR due to increase in medical tourism as well as increase in population. Numbers of companies in emerging countries are increasing due to increase in demand for disease diagnosis in clinics, hospitals and other areas. Additionally, the increasing number of healthcare expenditure and increasing number of hospitals and clinical diagnostic laboratories in China and India upsurge demand of clinical laboratory services. The Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of increasing infectious diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by laboratory for Clinical Laboratory Services and New Technology Penetration

Global clinical laboratory services market also provides you with detailed market analysis for every country growth in life science industry with clinical laboratory services demand impact of technological development in laboratory services and changes in regulatory scenarios with their support for the clinical laboratory services market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Clinical Laboratory Services Market Share Analysis

Global clinical laboratory services market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global clinical laboratory services market.

Many business expansion and developments are also initiated by the companies worldwide which are also accelerating the growth of global clinical laboratory services market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for Clinical Laboratory Services through expanded model range.

Customization Available:Global Clinical Laboratory Services Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-clinical-laboratory-services-market&rp

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Visit link:
Clinical Laboratory Services Market - Detailed Analysis of Current and Future Industry Figures till 2027 | Global Players Mayo Foundation for Medical...

UAE hails success of first bone marrow transplant – The National

By Stem Cell Medicine

The UAE is celebrating the success of its first bone marrow transplant.

Typically used to treat patients with blood and cancer disorders , the landmark procedure was carried out on a patient with multiple myeloma, a form of blood cancer.

While cancer is the third-highest cause of death across the Emirates, many Emirati citizens and residents have sought treatment abroad for cell therapy and regenerative medicine.

News of the successful transplant, which was the result of collaboration between Abu Dhabi Stem Cells Centre and Sheikh Khalifa Medical City, represents a major breakthrough for cancer patients living in the UAE who can now seek treatment closer to home to remain with family.

Researchers work to develop medication that can be used to treat Covid-19 patients, at Abu Dhabi Stem Cell Centre. Wam Twitter

Researchers work to develop medication that can be used to treat Covid-19 patients, at Abu Dhabi Stem Cell Centre. Wam Twitter

Researchers work to develop medication that can be used to treat Covid-19 patients, at Abu Dhabi Stem Cell Centre. Wam Twitter

Researchers work to develop medication that can be used to treat Covid-19 patients, at Abu Dhabi Stem Cell Centre. Wam Twitter

The doctors and researchers at Abu Dhabi Stem Cell Centre who were involved in the development of a potential Covid-19 treatment. CourtesyAbu Dhabi Stem Cell Centre

The milestone announcement comes as the centre launched the Abu Dhabi Bone Marrow Transplant programme on Monday.

"It fills us with great pride to be part of a first for the country and to make such a life-saving treatment available and accessible to those who need it here," said Dr Fatima Alkaabi, executive Director of the Abu Dhabi Bone Marrow Transplant programme.

"We are very grateful for the support and collaboration of SKMC in making this opportunity possible."

Bone marrow transplants are one of the most established stem cell-based therapies in the treatment of cancer, particularly blood cancers.

The unique procedure developed by the centre involved harvesting peripheral blood stem cells from the patient, who then underwent high-dose chemotherapy to eradicate all cancerous cells and most of the bone marrow.

The harvested stem cells were then infused back into the bloodstream, where they restore the destroyed cells and over the course of two weeks restart the production of healthy non-malignant blood cells.

"The patient is basically without an immune system while waiting for the transfused cells to take effect and must remain in isolation under the strictest infection control guidelines," said Dr Yendry Ventura, general manager of the stem cell centre and Abu Dhabi bone marrow transplant programme director.

"Since we are still in the midst of a global pandemic, we took additional precautions to ensure the best outcome possible for all involved."

Abu Dhabi Stem Cells Centre has been a driving force behind medical research in the country, including playing a key role in the ongoing fight against Covid-19.

Earlier last month, the team announced the results of the trial of its treatment for Covid-19 patients, branded UAECell19.

After opening in December, the centre has already received international press coverage over to its research into a treatment for the virus.

Their groundbreaking work has involved taking stem cells from a patients blood and returning them, via a nebuliser, as a fine mist to the lungs.

There they help regenerate lung cells and improve the body's immune response by preventing an overreaction to the infection that can damage healthy cells.

Updated: July 27, 2020 05:14 PM

Read more here:
UAE hails success of first bone marrow transplant - The National

Drug target for aggressive breast cancer found by team of UK and US scientists – iNews

By Stem Cell Medicine

The scientists said they were excited by their findings (Photo: ERIC PIERMONT/AFP/Getty)

A team of British and American scientists have discovered a way to slow the growth of breast cancer stem cells in the lab, which could eventually lead to combination drug therapies on previously untreatable forms of the disease.

Around three quarters of women who have breast cancer have what are known as oestrogen receptor positive tumours. Some breast cancer cells have receptors that bind to the hormone oestrogen and depend on it to grow. Though anti-oestrogen drugs such as tamoxifen and fulvestrant are able to prevent reoccurrence in most of these breast cancers, tumours reoccur in 1 out of 4 cases.

Many of the women relapse after several years, because some of the cancer cells remain after treatment. The cells, called cancer stem cells, lay dormant in the body and cannot be targeted by anti-oestrogen therapies.

Scientists have now found that cancer stem cells resistant to anti-oestrogen drugs express an immune system-related receptor, called interleukin 1 receptor. They also found that Anakinra, a drug used to treat rheumatoid arthritis, was able to reduce the ability of the cancer stem cells to grow.

However, the team said further research in animals and humans is needed before they can confirm if drugs targeting interleukin 1 receptor could be used as an effective treatment.

Scientists from the Universities of Michigan, Liverpool and Edinburgh were closely involved in the study led by Dr Bruno Simes and Professor Rob Clarke from The University of Manchester

Dr Simes said: Resistance to anti-oestrogen therapies in breast cancer patients is a major problem and one which cancer scientists have been trying to address for many years. Many drugs have been investigated by scientists as a possible combination therapy taken with anti-oestrogen therapies and we are still searching for a solution for these patients.

However, most of these drugs target actively dividing cells whereas we are trying to also target cells that are in a dormant state. So we hope that these women who have increased numbers of cancer stem cells and do not respond to currents treatment could one day benefit from combination therapy.

Theres a very long way to go before we can say if this approach will help these women but we are excited by our findings.

The study is published in the journal Stem Cell Reports.

Justin Stebbing, professor of cancer medicine and medical oncology at Imperial College London, said: Stem cells represent a very important target to understand better and eradicate, because they are responsible for some of the most worrying aspects of cancer, such as its ability to regrow, or be resistant to treatment. They are also a rare population but this laboratory research shows that cancer stem cells have on their surface a protein that we have a drug for interestingly one that is being trialled in Covid-19 too.

Hopefully, we can in the future link this laboratory work to research in women in the clinic, helping to reduce recurrence rates by eradicating rare stem cell populations that contribute to recurrence.

Baroness Delyth Morgan, chief executive at Breast Cancer Now, which helped fund the study, said: Its promising that targeting this protein [interleukin-1 receptor] may help reduce the growth of breast cancer stem cells, which are thought to be central to the disease spreading around the body, where it becomes incurable.

The development of resistance to hormone therapies remains a major challenge in the clinic. With around 11,500 women still dying from breast cancer each year in the UK, we urgently need to find new ways to prevent the disease spreading and to treat it more effectively when it does.

This exciting discovery highlights the importance of research to understand the molecular detail of how breast cancer spreads, and of investigating the potential of existing drugs to try to stop it. In particular, these findings offer further evidence that arthritis drugs such as Anakinra may be useful additions in treating breast cancer, and we hope further research can now help us fully understand their potential and whether and how they might work as a cancer treatment.

Excerpt from:
Drug target for aggressive breast cancer found by team of UK and US scientists - iNews

Scientists discover why coronavirus patients lose sense of smell and offer hope to those who havent got it – The Scottish Sun

By Stem Cell Doctors

THE KEY symptoms of coronavirus are now widely known as a new and persistent cough, a high temperature and a loss of taste and smell.

But many have been left mystified as to why the respiratory infection would prevent someone from being able to smell.

Read our coronavirus live blog for the latest news & updates

2

Now, scientists say they have the answer - and it's promising news if you're someone who still hasn't had their sense of smell back yet.

A team of experts at Harvard Medical School have identified the cell group which is most vulnerable to Covid-19.

They found the neurons that detect and transmit the sense of smell to the brain are not part of the vulnerable cells.

Researchers did however discover that the ACE 2 receptor protein that Covid uses to enter human cells is found in cells that provide metabolic and structural support.

Non neural cells are found in the central nervous system.

2

The experts said that their research suggests that it is these cells that are responsible for anosmia (loss of taste and smell) in Covid-19 patients.

Writing in Science Advancessenior study author Sandeep Robert Datta said: "Our findings indicate that the novel coronavirus changes the sense of smell in patients not by directly infecting neurons but by affecting the function of supporting cells.

"I think it's good news, because once the infection clears, olfactory neurons don't appear to need to be replaced or rebuilt from scratch."

They say that it means most people who develop anosmia due to Covid-19 will be able to regain their senses.

Anosmia is when you lose your sense of smell, which can be due to a number of different reasons.

The most common include:

It's estimated 6,000 people in the UK are born without a sense of smell and it can be diagnosed by doctors by usingacetylcysteinetests.

Often the condition can be unpleasant and affect your enjoyment of food.

It may go away in weeks or months by itself, but there are certain things you can do to alleviate it.

This includes rinsing the inside of your nose with a salt water solution, if your loss of smell has been caused by an infection or allergy.

You can also pick up sachets and a device from some pharmacies which can help you make a salt water solution.

The findings come after an alternative study found that one in ten coronavirus patients who lose their sense of taste and smell will not get it back.

Researchers compiled their data from Italian patients and found that 49 per cent had fully regained their sense of smell or taste after recovering from the virus.

This is while just 40 per cent reported improvements and 10 per cent said their symptoms had worsened.

Meanwhile analysis of electronic health records found that coronavirus patients are 27 times more likely to have a loss of smell but are 2.2 to 2.6 times more likely to have other respiratory difficulties compared to non Covid patients.

Datta and the team at Harvard looked to how a loss of sense and smell is altered in patients with Covid-19.

They found that cells that wrapped around sensory neurons (setentacular cells) provided metabolic support.

While basal cells helped regenerate after they were damaged.

Theolfactory epithelium is found in the nasal cavity and researchers found that these expressed higher levels of ACE 2 protein compared with resting stem cells.

Revealed

I may look sexy stripping, but usually l think about toast

The authors said that anosmia in Covid-19 patients could arise from a loss of supporting function in the olfactory epithelium which indirectly causes changes to olfactorysensory neurons.

Datta added: "Anosmia seems like a curious phenomenon, but it can be devastating for the small fraction of people in whom it's persistent.

"It can have serious psychological consequences and could be a major public health problem if we have a growing population with permanent loss of smell."

The team added that the research will offer hope to those who have not yet got their senses back as they claim it does not cause permanent damage.

Don't miss the latest news and figures - and essential advice for you and your family.

To receive The Suns Coronavirus newsletter in your inbox every tea time,sign up here.

To follow us on Facebook, simplyLike our Coronavirus page.

Get Britains best-selling newspaper delivered to your smartphone or tablet each day find out more.

See the original post:
Scientists discover why coronavirus patients lose sense of smell and offer hope to those who havent got it - The Scottish Sun

BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update – Yahoo Finance

By Adult Stem Cells

NEW YORK, July 27, 2020 /PRNewswire/ --BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2020, and provide a corporate update, at 8:00 a.m., Eastern Daylight Time (EDT), on Wednesday, August 5 2020.

On the call, BrainStorm CEO Chaim Lebovits will present a corporate update, including details on the timeline for the data readout of the Company's Phase 3 pivotal trial studying the safety and efficacy of NurOwn (MSC-NTF cell) in people with ALS. In addition, Dr. Revital Aricha. Brainstorm's Vice President of Research and Development, will provide an R&D update including recently announced data from the Company's groundbreaking preclinical study evaluating NurOwn-derived exosomes for the treatment of COVID-19 ARDS.

Thereafter, senior management officers will join the call for a Q&A session. Participants are encouraged to submit their questions prior to the call by sending them to:q@brainstorm-cell.com. Questions should be submitted by5:00 p.m. EDT,Monday, August 3, 2020.

Teleconference Details BRAINSTORM CELL THERAPEUTICS 2Q 2020

The investment community may participate in the conference call by dialing the following numbers:

Participant Numbers:

Toll Free: 877-407-9205 International: 201-689-8054

Those interested in listening to the conference call live via the internet may do so by visiting the "Investors & Media" page of BrainStorm's website atwww.ir.brainstorm-cell.comand clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

Replay Number:

Toll Free: 877-481-4010 International: 919-882-2331 Replay Passcode: 36017

Teleconference Replay Expiration:

Wednesday, August 19, 2020

About NurOwn

NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received acceptance from theU.S. Food and Drug Administration(FDA) to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS) and initiated enrollment inMarch 2019.

AboutBrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(FDA) and theEuropean Medicines Agency(EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at sixU.S.sites supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a filing forU.S.FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently receivedU.S.FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment inMarch 2019. For more information, visit the company's website atwww.brainstorm-cell.com.

Story continues

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Investor Relations:Preetam Shah, MBA, PhD Chief Financial Officer BrainStorm Cell Therapeutics Inc. Phone: +1-862-397-1860 pshah@brainstorm-cell.com

Media:Paul Tyahla SmithSolve Phone: +1-973-713-3768 Paul.tyahla@smithsolve.com

View original content:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-announce-second-quarter-financial-results-and-provide-a-corporate-and-rd-update-301100141.html

SOURCE Brainstorm Cell Therapeutics Inc

Go here to read the rest:
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update - Yahoo Finance

Induced Pluripotent Stem Cells Market is Expected to Grow at a CAGR of 7% During the Forecast Period 2026 – Market Research Posts

By Stell Cell Research

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/17968

Company Profile

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/17968

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition.

This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation.

A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/17968

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Key Questions Answered in Market Report:

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Feminine Hygiene Product Market Feminine Hygiene Products Market Segmented By Sanitary Pads/Napkins, Tampons, Panty Liners, Menstrual Cups, and Feminine Hygiene Wash.For More Information

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish Kolte Persistence Market Research Address 305 Broadway, 7th FloorNew York City, NY 10007 United States U.S. Ph. +1-646-568-7751 USA-Canada Toll-free +1 800-961-0353 Sales[emailprotected] Websitehttps://www.persistencemarketresearch.com

See original here:
Induced Pluripotent Stem Cells Market is Expected to Grow at a CAGR of 7% During the Forecast Period 2026 - Market Research Posts

Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health – BioSpace

By Stell Cell Research

INGELHEIM, Germany--(BUSINESS WIRE)-- Boehringer Ingelheim, a market leader in animal health, has acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company. GST is dedicated to the research, development and production of evidence-based, regenerative medicines (stem cell therapies) used to treat orthopedic and metabolic diseases in animals. Boehringer Ingelheim already entered into a partnership with GST in 2018; in 2019, the companies launched Arti-Cell Forte in Europe.

Arti-Cell Forte is testimony to the innovation strength that lies within both companies. It is the first-ever stem cell product in the veterinary world granted marketing authorization by the European Commission. The acquisition and integration of GST will accelerate the development pipeline of Boehringer Ingelheim while maintaining its focus on setting new standards of care for animals.

Collaboration with external partners plays an essential role in helping us expand our portfolio. After two years of a very successful partnership, we have decided to acquire GST. We are convinced that its expertise in the field of state-of-the art stem cell products will help us bring even more innovative solutions to our customers, shares Jean-Luc Michel, Head of Global Strategic Marketing, Boehringer Ingelheim Animal Health.

Boehringer Ingelheim wants to lead a new wave of innovation in the veterinary field. This ambition is a natural fit with GSTs management, staff and vision. From the very beginning we aimed to change the veterinary field, a role we will continue to play as a new R&D division within Boehringer Ingelheim, says Jan Spaas, CEO of GST.

This decision is fully aligned with our recently refocused strategic direction. Stem cell research areas and regenerative medicine offer an exciting potential for the next wave of innovation we are actively pursuing. In addition, strengthening external partnerships to accelerate our innovative efforts and growth is one of the key elements of our strategy, adds Eric Haaksma, Head of Global Innovation at Boehringer Ingelheim Animal Health.

The companies did not disclose the financial terms of the deal.

For references and notes to editors, please visit:

http://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-acquires-global-stem-cell-technology

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005234/en/

Follow this link:
Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health - BioSpace

3D Cell Culture Market Size, Share Global Comprehensive Research Study,Trends, Development Status, Opportunities, Future Plans, Competitive Landscape…

By Stell Cell Research

Global 3D Cell Culture Market Report Focuses on the key 3D Cell Culture Market manufacturers, to study the sales, value, market share and development plans in the future. It is Define, describe and forecast the 3D Cell Culture Market by type, application, and region to Study the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. Know significant trends and factors driving or inhibiting the 3D Cell Culture Market growth opportunities in the market for stakeholders by identifying the high growth segments. Strategically it examines each submarket with respect to individual growth trend and their contribution to the 3D Cell Culture Market

Get a sample copy of the report at https://www.marketreportsworld.com/enquiry/request-sample/12524335

The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2020 to 2020.

The cell culture technique is present in biological areas for the development of drug discovery, regenerative medicine, and protein production The cell culture technique has evolved from 2D cell culture to 3D cell culture The 3D culture resembles physiological conditions closely and has various different advantages over the 2D culture conditions The 3D cell culture can be defined as the culture of living cells within micro-assembled devices and supports the display of three-dimensional structures mimicking tissue and organ-specific microarchitecture The factors driving the market include increasing application of biotech and pharmaceutical companies and hospitals and rise in the patient population affected by cancer The growing number of patients in need of organ transplantation is propelling the growth of the market However, the high cost of devices, regulatory framework, and lack of awareness amongst the masses are major challenges for the market The global market for 3D cell culture is segmented on the basis of technique, product, application, end user, and region On the basis type of technique, it is segmented into scaffold-based 3D cell culture and scaffold-free 3D cell culture The scaffold-based 3D cell culture is further segmented into hydrogel-based support and polymeric hard material based support The scaffold-free 3D cell culture is further segmented into hanging drop microplates, spheroid microplates containing ultra-low attachment (ULA) coating, and microfluidic 3D cell culture On the basis of product, it is segmented into consumables and instruments The consumables are further segmented into culture media, reagents, 3D multi-well plates, and glassware The instruments are further segmented into bioreactor, flow cytometer, and cell culture chips On the basis of application, it is segmented into drug discovery, cancer research, stem cell research, tissue screening and engineering, and regenerative medicine On the basis of end users, it is segmented into pharmaceutical and biotechnology companies, contract research organizations, and research and academic laboratoriesThe global 3D cell culture market accounted for USD 725

Here is List of Top 3D Cell Culture Market Key-Manufactures:

Global 3D Cell Culture market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global 3D Cell Culture market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Enquire before purchasing this report https://www.marketreportsworld.com/enquiry/pre-order-enquiry/12524335

The overviews, SWOT analysis and strategies of each vendor in the 3D Cell Culture market provide understanding about the market forces and how those can be exploited to create future opportunities. Major points like Competitive Situation and Trends, Concentration Rate Mergers & Acquisitions, Expansion which are vital information to grow/establish a business is also provided.

Key Factors Involved in the Report:

3D Cell Culture Market Forecast by regions, type and application, with sales and revenue, from 2020 to 2020.

3D Cell Culture Market Share, distributors, major suppliers, changing price patterns and the supply chain of raw materials is highlighted in the report.

3D Cell Culture Market Size (sales, revenue) forecast by regions and countries from 2020 to 2020 of 3D Cell Culture industry.

The global 3D Cell Culture market Growth is anticipated to rise at a considerable rate during the forecast period, between 2020 and 2020. In 2020, the market was growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

3D Cell Culture Market Trend for Development and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

3D Cell Culture Market Report also mentions market share accrued by each product in the 3D Cell Culture market, along with the production growth.

The study objectives of this report are:

Target Audience

Production Analysis: SWOT analysis of major key players of 3D Cell Culture industry based on a Strengths, Weaknesses, companys internal & external environments, Opportunities and Threats. It also includes Production, Revenue, and average product price and market shares of key players. Those data are further drilled down with Manufacturing Base Distribution, Production Area and Product Type.

Regional analysis

Geographically, the global 3D Cell Culture market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Key Features of 3D Cell Culture Market Research Report:

Purchase this report (Price 4450 USD for a single-user license) https://www.marketreportsworld.com/purchase/12524335

Total Chapters in 3D Cell Culture Market Report are:

Chapter 1 Overview of 3D Cell Culture Market

Chapter 2 Global Market Status and Forecast by Regions

Chapter 3 Global Market Status and Forecast by Types

Chapter 4 Global Market Status and Forecast by Downstream Industry

Chapter 5 North America Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 6 Europe Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 7 Asia Pacific Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 8 Latin America Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 9 Middle East and Africa Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 10 Market Driving Factor Analysis of Low End Servers

Chapter 11 3D Cell Culture Market Competition Status by Major Manufacturers

Chapter 12 3D Cell Culture Major Manufacturers Introduction and Market Data

Chapter 13 Upstream and Downstream Market Analysis of 3D Cell Culture Market

Chapter 14 Cost and Gross Margin Analysis of 3D Cell Culture Market

Browse complete table of contents at https://www.marketreportsworld.com/TOC/12524335

About Us:

Market Reports Worldis the Credible Source for Gaining the Market Reports that will Provide you with the Lead Your Business Needs. Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.

CONTACT US

Name: Ajay More

Email: [emailprotected]

Phone: US +1 424 253 0807 /UK +44 203 239 8187

Other Reports Here:

Household Food Containers Market Share,Size 2020 Global Industry Brief Analysis by Top Countries Data, Strategic Initiatives, Competitors, Industry Peers, News and significant Growth With Regional Trends By Forecast 2024

Organic Dairy Products Market 2020 Size,Share Global Trend Factor, Segmentation, Business Growth, Top Key Players Analysis Industry, Opportunities and Forecast to 2024

Lipid Metabolism Disease Treatment Market 2020 Share, Size Global Development Status, Sales Revenue, Emerging Technologies, Key Players Analysis, Opportunity Assessment and Industry Expansion Strategies 2025

RFID Blood Refrigerator and Freezer Market Share, Size Global Competition Strategies, Statistics, Industry Trends, Revenue Analysis, Key Players, Regional Analysis by Forecast to 2026

Dental Bonding Agents Market Size,Share ,Global Growth Insights to 2026 by Recent Business Growth, Regional Demand, Segmentation and Competitive Analysis Research Report

Diabetes Market Share, Size Global Regional Overview, Opportunities, Trends, Global Growth,Impact of Covid-19 on Industry, Leading Company Analysis, And Key Country Forecast to 2025

View post:
3D Cell Culture Market Size, Share Global Comprehensive Research Study,Trends, Development Status, Opportunities, Future Plans, Competitive Landscape...

Can progenitor cells go further than gene therapy in retinal disorders? A biotech’s answer shines in PhIIb – Endpoints News

By Stem Cell Treatment

By the time the FDA approved Luxturna the pioneering gene therapy for an inherited retinal disease Henry Klassen had been researching and treating the group of diseases known as retinitis pigmentosa for more than 20 years.

Spark Therapeutics success there had not just inspired a $4.3 billion takeover by Roche, it had also emboldened other biotechs pursuing a therapy that would deliver one of the genes tied to different variations of the disorder. Nightstar Therapeutics subsequently scored its own buyout with Biogen, and MeiraGTx recently posted early but exciting data on its J&J-partnered program.

But Klassen went a different way.

Catching on the stem cell craze right at the turn of the millennium, he took inspiration from scientists who transplanted neural progenitor cells into the retina and developed a method to grow retinal progenitor cells instead as a therapy. Starting out as the director of stem cell research at the Childrens Hospital of Orange County, he continued the work at the University of California, Irvine, eventually spinning out a biotech dubbed jCyte in 2012.

Over the weekend jCyte reported positive Phase IIb results from what they call one of the largest studies ever conducted in RP, suggesting that patients on the treatment saw improved functional vision compared to the placebo group.

The credit to the gene therapies is that theyre actively trying to fix the gene underlying the problem. Thats very commendable, and were not doing that, Klassen told Endpoints News. But our treatment as it stands should have impact across a variety of different genotypes.

The study enrolled a total of 84 patients, of whom 74 were included for the final analysis. For each patient on the primary endpoint of best corrected visual acuity (measured with glasses on), the mean change from baseline to month 12 for the sham, low dose and high dose arms were +2.81, +2.96, and +7.43 letters, respectively.

In a post hoc analysis for a target subgroup, the difference was even more prominent: +1.85, -0.15, and +16.27 letters, respectively.

There was one serious adverse event in the low dose arm, but jCyte said the grade 3 ocular hypertension resolved with treatment and other side effects were generally minor.

CEO Paul Bresge noted that the target subgroup analysis was intended to hammer out the criteria they might use to recruit patients into Phase III which would likely have a similar design and use the same primary endpoint of BCVA, the gold standard in the context of FDA. The late-stage trial is slated for 2021.

We did enroll a very wide patient population into our Phase IIb, including patients that had vision anywhere from 20/80 to 20/800, just to learn which patients would potentially be the best responders, he said.

The target subgroup is characterized by having reliable fixation on the study eye, and a study eye that does not have significantly worse BCVA (15 letters) than the fellow eye.

He added that investigators also observed encouraging results with the secondary endpoints such as low light mobility, contrast sensitivity kinetic visual fields and a vision function questionnaire, although the data werent disclosed.

Typically people think about the disease as a narrowing of this peripheral vision in a very nice granular way, but thats actually not what happens, he said about the visual fields finding. What happens in the disease is that patients lose like islands of vision. So what were doing in our tests is actually measuring [] islands that the patients have at baseline, and then what were seeing after treatment is that the islands are expanding. Its similar to the way that one would track, lets say a tumor, in oncology of course were looking for the opposite effect. Were looking for the islands of vision to expand.

The therapy works primarily by preserving photoreceptors, Klassen posits, not by generating new ones. But what he thinks is happening is that photoreceptors are regenerating the outer segment if photoreceptors are radios, these would be the antenna thereby regaining some function.

That could position it as a treatment for a different stage of the disease than Sparks or Nightstars. Klassen, whos also researching retinal reconstruction using stem cells, is happy to not view it through the competitive lens.

If you look into the future, one could imagine that gene therapies will be most effective very early in the course of a disease before photoreceptors are lost, he said. Then as photoreceptors begin to be lost anyway, if that happens, then a therapy like ours would become extremely valuable. And if ours starts to lose power late in the course of a disease, maybe cell transplantation under the retina could have a role.

Go here to see the original:
Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb - Endpoints News

→←